Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus NEPHRAMINE 5 4.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN 7 W ELECTROLYTES versus NEPHRAMINE 5 4.
AMINOSYN 7% W/ ELECTROLYTES vs NEPHRAMINE 5.4%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amino acids are the building blocks for protein synthesis in the body. This solution provides essential and non-essential amino acids to maintain nitrogen balance and support tissue repair and growth when oral intake is inadequate.
Provides essential amino acids for protein synthesis in patients with renal impairment, reducing nitrogen waste accumulation.
Intravenous infusion at 1-1.5 g amino acids/kg/day. Typical adult dose: 500 mL of 7% solution (35 g amino acids) infused over 8-12 hours, repeated daily as per nitrogen requirements.
500 mL to 1000 mL intravenously over 8-24 hours, containing 5.4% amino acids, typically as a component of total parenteral nutrition; dose adjusted based on metabolic needs and protein requirements (usual 0.8-1.5 g/kg/day amino acids).
None Documented
None Documented
Terminal elimination half-life for the constituent amino acids ranges from 0.5 to 4 hours, depending on the specific amino acid and metabolic state. Clinically, infusion rate should be adjusted to avoid accumulation in renal impairment.
1-2 hours (endogenous amino acid pool turnover); clinical context: continuous infusion required to maintain plasma levels.
Primarily renal. Amino acids are deaminated, and nitrogen is excreted as urea in urine. Biliary/fecal excretion is negligible. Almost 100% of infused amino acids are either metabolized or excreted as urea and other nitrogenous wastes.
Renal: >90% as amino acids and metabolites. Biliary/fecal: negligible.
Category C
Category C
Amino Acid Solution
Amino Acid Solution